Results indicated that serum anti-AQP4 antibodies were positively detected in 87 (85.9%) patients, optic neuritis in 22 (23.3%), myelitis in 48.54%, and brain attacks and mixed attacks in 34 (28.16%). This evidence concerns the gene AQP4 and optic neuritis.